GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Debt-to-EBITDA

Zynex (ZYXI) Debt-to-EBITDA : 5.51 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Zynex Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zynex's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.9 Mil. Zynex's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $72.2 Mil. Zynex's annualized EBITDA for the quarter that ended in Dec. 2023 was $13.8 Mil. Zynex's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 5.51.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zynex's Debt-to-EBITDA or its related term are showing as below:

ZYXI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.1   Med: 0.5   Max: 4.26
Current: 4.26

During the past 13 years, the highest Debt-to-EBITDA Ratio of Zynex was 4.26. The lowest was -2.10. And the median was 0.50.

ZYXI's Debt-to-EBITDA is ranked worse than
73.33% of 75 companies
in the Medical Distribution industry
Industry Median: 1.87 vs ZYXI: 4.26

Zynex Debt-to-EBITDA Historical Data

The historical data trend for Zynex's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Debt-to-EBITDA Chart

Zynex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.62 1.42 1.05 4.26

Zynex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 2.41 3.24 2.98 5.51

Competitive Comparison of Zynex's Debt-to-EBITDA

For the Medical Distribution subindustry, Zynex's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zynex's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Zynex's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zynex's Debt-to-EBITDA falls into.



Zynex Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zynex's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.925 + 72.243) / 17.893
=4.26

Zynex's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.925 + 72.243) / 13.82
=5.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Zynex  (NAS:ZYXI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zynex Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zynex's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynex (ZYXI) Business Description

Traded in Other Exchanges
N/A
Address
9555 Maroon Circle, Englewood, CO, USA, 80112
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.
Executives
Daniel J Moorhead officer: Chief Financial Officer 9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok officer: See Remarks 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard director, 10 percent owner, officer: President, CEO and Chairman 10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery officer: See Remarks C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow director AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress director 3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc 10 percent owner 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea officer: Chief Operating Officer C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112